Aratana Therapeutics Inc. (NASDAQ:PETX) rose 9.2% during mid-day trading on Tuesday . The company traded as high as $9.39 and last traded at $9.34, with a volume of 1,023,652 shares changing hands. The stock had previously closed at $8.55.

PETX has been the subject of a number of research reports. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research report on Thursday, July 7th. Lake Street Capital reissued a “buy” rating and set a $15.00 price target on shares of Aratana Therapeutics in a research report on Sunday, July 17th. Finally, William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Aratana Therapeutics currently has an average rating of “Buy” and a consensus price target of $11.66.

The company’s 50-day moving average price is $6.82 and its 200 day moving average price is $5.63. The firm’s market capitalization is $320.51 million.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.37. The firm had revenue of $38.05 million for the quarter, compared to analysts’ expectations of $15.14 million. During the same quarter in the prior year, the business posted ($0.23) earnings per share. On average, analysts forecast that Aratana Therapeutics Inc. will post ($1.02) EPS for the current fiscal year.

In other Aratana Therapeutics news, insider Ernst Heinen sold 15,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $6.72, for a total transaction of $100,800.00. Following the transaction, the insider now directly owns 125,494 shares in the company, valued at $843,319.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Julia A. Stephanus sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total value of $187,500.00. Following the transaction, the insider now owns 127,503 shares in the company, valued at $796,893.75. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.